SCANDION ONC. DK-0735 Market Cap ($140.86K)
Market Cap & Net Worth: SCANDION ONC. DK-0735 (8VY)
SCANDION ONC. DK-0735 market cap. SCANDION ONC. DK-0735 (F:8VY) has a market capitalization of $140.86K (€120.48K) as of November 3, 2026. Listed on the F stock exchange, this Germany-based company holds position #31437 globally and #2797 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SCANDION ONC. DK-0735's stock price €0.00 by its total outstanding shares 234762000 (234.76 Million).
SCANDION ONC. DK-0735 Market Cap History (2021–2025)
SCANDION ONC. DK-0735 market cap history from 2021 to 2025. Data shows change from $325.51 Million to $164.68K (-83.46% CAGR). Check 8VY stock price and chart for real-time trading data and today's change.
SCANDION ONC. DK-0735 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SCANDION ONC. DK-0735's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 8VY by Market Capitalization
Companies near SCANDION ONC. DK-0735 in the global market cap rankings as of November 3, 2026.
Key companies related to SCANDION ONC. DK-0735 by market ranking:
- Tasty Plc (LSE:TAST): Ranked #31428 globally with a market cap of $144.44K USD ( GBX1.19 Billion GBX).
- Residential Secure Income plc (LSE:RESI): Ranked #31429 globally with a market cap of $144.19K USD ( GBX1.19 Billion GBX).
- Power Metal Resources plc (LSE:POW): Ranked #31438 globally with a market cap of $139.68K USD ( GBX1.15 Billion GBX).
- DSW Capital PLC (LSE:DSW): Ranked #31439 globally with a market cap of $139.13K USD ( GBX1.14 Billion GBX).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #31428 | Tasty Plc | LSE:TAST | $144.44K | GBX0.53 |
| #31429 | Residential Secure Income plc | LSE:RESI | $144.19K | GBX6.40 |
| #31438 | Power Metal Resources plc | LSE:POW | $139.68K | GBX10.10 |
| #31439 | DSW Capital PLC | LSE:DSW | $139.13K | GBX45.50 |
Market Capitalization of SCANDION ONC. DK-0735 (2021–2025)
Market capitalization of SCANDION ONC. DK-0735 from 2021 to today. Between 2021 and today, SCANDION ONC. DK-0735's market cap moved from $325.51 Million to $ 164.68K, with a yearly change of -83.46%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €164.68K | -90.91% |
| 2024 | €1.81 Million | -97.93% |
| 2023 | €87.42 Million | +61.68% |
| 2022 | €54.07 Million | -83.39% |
| 2021 | €325.51 Million | -- |
End of Day Market Cap According to Different Sources
On Jul 10th, 2026 the market cap of SCANDION ONC. DK-0735 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $140.86K USD |
| MoneyControl | $140.86K USD |
| MarketWatch | $140.86K USD |
| marketcap.company | $140.86K USD |
| Reuters | $140.86K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SCANDION ONC. DK-0735
Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for tr… Read more